Novartis AG ADR (NVS)vsTriSalus Life Sciences Inc. (TLSI)
NVS
Novartis AG ADR
$146.57
-0.87%
HEALTHCARE · Cap: $282.11B
TLSI
TriSalus Life Sciences Inc.
$4.39
+1.62%
HEALTHCARE · Cap: $275.75M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 125208% more annual revenue ($56.58B vs $45.15M). NVS leads profitability with a 23.9% profit margin vs -86.9%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
TLSI
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$146.57
$36.97 premium
Margin of Safety
-51.4%
Fair Value
$3.15
Current Price
$4.39
$1.24 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Revenue surging 59.8% year-over-year
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -496.2% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : TLSI
The strongest argument for TLSI centers on Revenue Growth. Revenue growth of 59.8% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : TLSI
The primary concerns for TLSI are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while TLSI is a hypergrowth play — different risk/reward profiles.
TLSI carries more volatility with a beta of 0.54 — expect wider price swings.
TLSI is growing revenue faster at 59.8% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 25/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →TriSalus Life Sciences Inc.
HEALTHCARE · MEDICAL DEVICES · USA
TriSalus Life Sciences Inc. (TLSI) is an innovative biopharmaceutical company at the forefront of transforming cancer therapy through its proprietary localized drug delivery systems. By optimizing the efficacy of immuno-oncology agents and tackling significant distribution hurdles within the tumor microenvironment, TriSalus aims to enhance therapeutic outcomes for cancer patients. The company boasts a compelling pipeline of clinical programs that underscore its dedication to addressing the pressing need for advanced cancer treatments. With a strategic vision centered on expanding access to these critical therapies, TriSalus is positioned to be a significant player in the evolving oncology sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?